PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
Phase 1
Completed
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2006-03-16
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 76
- Registration Number
- NCT00303290
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- Head and Neck Cancer
- Interventions
- Biological: CetuximabProcedure: Conventional SurgeryRadiation: Radiation Therapy
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00301028
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00299156
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00299182
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Group Therapy for Nicotine Dependence: Mindfulness and Smoking
Not Applicable
Completed
- Conditions
- SmokingTobacco Use Cessation
- Interventions
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 650
- Registration Number
- NCT00297479
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00294632
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00290433
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of ZD6474 in Advanced NSCLC
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00290537
- Locations
- 🇺🇸
University of Texas M.D.Anderson Cancer Center, Houston, Texas, United States
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00290511
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
Phase 2
Completed
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 67
- Registration Number
- NCT00290498
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath